Bio-Rad Laboratories heads into the post-earnings stretch with a sharp divergence between what options markets are saying and what short sellers are actually doing.
The clearest signal this week is in options. Demand for downside protection has jumped well above normal — the put/call ratio hit 0.55 on Tuesday, more than two and a half standard deviations above its 20-day mean of 0.23. That z-score of 2.69 is among the more elevated readings in the past year, even if the ratio itself remains far below the 52-week high of 2.98 set during more acute stress. The timing matters: Bio-Rad just reported Q2 results on August 4th, and the stock has barely moved — down half a percent on the day and up less than 1% on the week to $332.88. Options traders appear to be hedging against a delayed reaction or a deterioration in the macro backdrop rather than an immediate print-driven move.
Short interest tells a more constructive story. Bears have been paring back. Short interest as a percentage of the free float fell 7.1% over the past week to 6.8% of float — down from a recent peak just above 7.5% in late July. The borrow market is not flashing any distress: cost to borrow runs at just 0.55%, barely changed and firmly in low territory. Availability is ample at roughly 319%, well above the 52-week floor of 241%, meaning there is no supply constraint pressuring existing shorts to cover. The ORTEX short score has eased from 57.3 on July 30th to 54.0 today — still above neutral, but the direction is clearly softening. Positioning looks cautious rather than crowded, with shorts retreating even as options hedgers pick up activity.
The Street is sending mixed signals, though the tone shifted meaningfully on August 5th. RBC Capital's Dan Leonard raised his target from $320 to $370, maintaining Outperform — a notable move from a bellwether that reinstated coverage only in May. Wells Fargo also nudged its target up to $330 from $310, though the Equal-Weight rating signals the firm sees limited upside from here. The current mean price target of $321 actually sits slightly below Wednesday's close, suggesting the Street as a whole had not yet fully priced in the post-earnings move before these revisions hit. Bio-Rad's EPS surprise factor scores in the 98th percentile of its universe — the company has a strong recent record of beating estimates — and the price-to-earnings multiple has expanded roughly 2.8 points over the past 30 days to 34.5x, reflecting the 12% one-month price rally. The bear case centres on a $40 million revenue headwind from declining federal funding for academic customers, a steeper cut than peers like TMO and AVTR are absorbing. Bulls point to ERP-driven margin improvements and recovery potential in the clinical diagnostics business, which accounts for roughly 60% of revenue.
Peer performance this week reinforces the cautious mood in the broader sector. TMO fell 2% on the week and DHR dropped 2.1%, while BLFS and SRT3 managed modest gains of 1.7% and 2.3% respectively. BIO's flat weekly performance sits roughly in the middle of its peer group — neither leading the recovery nor amplifying the sector weakness.
Insider activity adds little colour this week. The only recent transaction was a small tax-withholding sale by a divisional president on July 24th — 89 shares at $314 — tied to a routine equity award. Net insider activity over the past 90 days is modestly positive at roughly $164,000, but the transactions are all award-related and carry significance scores of 1. There is no meaningful insider signal here either way.
What to watch next: the gap between the options market's defensive posture and short sellers' retreat will clarify as the Street digests RBC's upgraded $370 target against a mean consensus that remains below the current price — and whether the federal-funding headwind materialises more broadly across Q3 guidance from peers reporting in the weeks ahead.
See the live data behind this article on ORTEX.
Open BIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
